According to new research that was presented at the second Asia Pacific Stroke Conference in Tokyo, researchers have been able to confirm that in Asian populations, the drug Dabigatran is better at managing AF patients than Warfarin.

This new sub-analysis of the RE-LY clinical trial is showing that Dabigatran is continuously proving itself to be better than Warfarin at treating AF patients in this part of the population. Previous studies have shown that where someone lives plays a significant role in what type of treatment patients receive and respond well to, and that it can also play a part in the patients’ outcomes. This analysis was conducted with researchers evaluating 2,782 patients with AF who live in Asian countries. According to an article published online at Menafn, “benefits were consistent across both Asian and non-Asian groups with Pradaxa 150 mg bid showing larger risk reductions in stroke and SE compared to Warfarin (rates of stroke/SE in Asia were 1.39 percent per year on Pradaxa 150 mg bid, 2.50 percent per year on Pradaxa 110 mg bid and as high as 3.06 percent per year on Warfarin).”

What this means is that the researchers found that the Asian patients had a significantly lower rate of bleeding using the Pradaxa than the Asian patients did on Warfarin.

“The findings of this study reaffirm the efficacy and safety of Dabigatran etexilate for the treatment of people living with atrial fibrillation around the world,” commented Gregory Lip, professor of cardiovascular medicine at University of Birmingham Centre for Cardiovascular Sciences, UK, on the findings. “This analysis provides doctors who are practicing in this region with further guidance and support for the use of this oral anticoagulant and the benefits that it can deliver to patients.”

Atrial fibrillation is a serious condition that causes the heart to beat in an irregular fashion; the patient often experiences what he or she will describe as “flutters.” The condition is treated with numerous medications including the anticoagulant Multaq. Research has shown that Multaq causes liver failure and a worsening of the heart condition for some patients.

If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.